| 利用者成果(英) |
|
21426
Machino H, Dozen A, Konaka M, Komatsu M, Nakamura K, Ikawa N, Shozu K, Asada K, Kaneko S, Yoshida H, Kato T, Nakayama K, Saloura V, Kyo S, Hamamoto R.
Integrative analysis reveals early epigenetic alterations in high-grade serous ovarian carcinomas.
Exp Mol Med
2023
PubMed ID: 37779141
DOI: 10.1038/s12276-023-01090-1
|
|
21483
Tsuchimochi S, Wada-Hiraike O, Urano Y, Kukita A, Yamaguchi K, Honjo H, Taguchi A, Tanikawa M, Sone K, Mori-Uchino M, Tsuruga T, Oda K, Osuga Y.
Characterization of a fluorescence imaging probe that exploits metabolic dependency of ovarian clear cell carcinoma.
Sci Rep
2023
13(1):20292
PubMed ID: 37985723
DOI: 10.1038/s41598-023-47637-0
|
|
20521
Machino H, Kaneko S, Komatsu M, Ikawa N, Asada K, Nakato R, Shozu K, Dozen A, Sone K, Yoshida H, Kato T, Oda K, Osuga Y, Fujii T, von Keudell G, Saloura V, Hamamoto R.
The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma.
Commun Biol
2022
5(1):39
PubMed ID: 35017636
DOI: 10.1038/s42003-021-02992-4
|
|
20800
Fu L, Zhang D, Yi N, Cao Y, Wei Y, Wang W, Li L.
Circular RNA circPBX3 promotes cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression.
Hum Cell
2022
PubMed ID: 35907138
DOI: 10.1007/s13577-022-00748-8
|
|
20428
Yang X, Wu G, Yang F, He L, Xie X, Li L, Yang L, Ma Y, Zhang Q, Chen J, Zou S, Han Q, Wang Y, Liu S, Li J, Han B, Liu K.
Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis.
Oxid Med Cell Longev
2021
2021:5574130
PubMed ID: 34336102
DOI: 10.1155/2021/5574130
|
|
13387
Wada M, Kukita A, Sone K, Hamamoto R, Kaneko S, Komatsu M, Takahashi Y, Inoue F, Kojima M, Honjoh H, Taguchi A, Kashiyama T, Miyamoto Y, Tanikawa M, Tsuruga T, Mori-Uchino M, Wada-Hiraike O, Osuga Y, Fujii T.
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
Biomolecules
2020
PubMed ID: 33339442
DOI: 10.3390/biom10121686
|
|
13700
Kudo K, Nomura M, Sakamoto Y, Ito S, Morita M, Kawai M, Yamashita Y, Ito K, Yamada H, Shima H, Yaegashi N, Tanuma N.
Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer
FEBS Lett
2020
594(9):1379-1388
PubMed ID: 31950503
DOI: 10.1002/1873-3468.13736
|
|
11501
Kukita A, Sone K, Oda K, Hamamoto R, Kaneko S, Komatsu M, Wada M, Honjoh H, Kawata Y, Kojima M, Oki S, Sato M, Asada K, Taguchi A, Miyasaka A, Tanikawa M, Nagasaka K, Matsumoto Y, Wada-Hiraike O, Osuga Y, Fujii T.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Biochem. Biophys. Res. Commun.
2019
PubMed ID: 30955858
DOI: 10.1016/j.bbrc.2019.03.155
|
|
11511
Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature
2019
PubMed ID: 30971826
DOI: 10.1038/s41586-019-1103-9
|
|
18200
Hiramatsu K, Serada S, Enomoto T, Takahashi Y, Nakagawa S, Nojima S, Morimoto A, Matsuzaki S, Yokoyama T, Takahashi T, Fujimoto M, Takemori H, Ueda Y, Yoshino K, Morii E, Kimura T, Naka T.
LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake
Cancer Res
2018
78(2):516-527
PubMed ID: 29187404
DOI: 10.1158/0008-5472.CAN-17-0910
|
|
9659
Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R Grassian, Igor Feldman, Sarah K Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A Copeland, Richard Chesworth, Jesse J Smith, Heike Keilhack, Scott A Ribich
Selective Killing of SMARCA2- And SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Mol Cancer Ther
2017
16(5):850-860
PubMed ID: 28292935
DOI: 10.1158/1535-7163.MCT-16-0678
|
|
9658
Tomoko Kashiyama, Katsutoshi Oda, Yuji Ikeda, Yoshinobu Shiose, Yasuhide Hirota, Kanako Inaba, Chinami Makii, Reiko Kurikawa, Aki Miyasaka, Takahiro Koso, Tomohiko Fukuda, Michihiro Tanikawa, Keiko Shoji, Kenbun Sone, Takahide Arimoto, Osamu Wada-Hiraike, Kei Kawana, Shunsuke Nakagawa, Koichi Matsuda, Frank McCormick, Hiroyuki Aburatani, Tetsu Yano, Yutaka Osuga, Tomoyuki Fujii
Antitumor Activity and Induction of TP53-dependent Apoptosis Toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
PLoS One
2014
9(2):e87220
PubMed ID: 24504419
DOI: 10.1371/journal.pone.0087220
|
|
9669
Ikue Nakayama, Masahiko Shibazaki, Akiko Yashima-Abo, Fumiharu Miura, Toru Sugiyama, Tomoyuki Masuda, Chihaya Maesawa
Loss of HOXD10 Expression Induced by Upregulation of miR-10b Accelerates the Migration and Invasion Activities of Ovarian Cancer Cells
Int J Oncol
2013
43(1):63-71
PubMed ID: 23670532
DOI: 10.3892/ijo.2013.1935
|
|
15560
Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, Sasano H, Yaegashi N.
Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
Cancer Sci
2008
99:2365-72
PubMed ID: 19032364
DOI: 10.1111/j.1349-7006.2008.00988.x
|
戻る
細胞材料の再培養方法 (
HPS以外・
HPS )
ページトップへ
細胞材料開発室サイト
